Bispecific monoclonal antibodies (bsAbs) are a class of engineered antibodies capable of simultaneously binding to two different antigens or epitopes. This dual-targeting ability allows them to bring together immune cells and cancer cells, promoting a more effective immune response against tumors. Unlike traditional monoclonal antibodies, which bind to a single target, bsAbs can engage multiple pathways and mechanisms, providing a multifaceted approach to cancer therapy.
